{"name":"AUG Therapeutics","slug":"aug-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AVTX-803","genericName":"AVTX-803","slug":"avtx-803","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AVTX-803 (L-Fucose)","genericName":"AVTX-803 (L-Fucose)","slug":"avtx-803-l-fucose","indication":"Advanced solid tumors (in combination with monoclonal antibodies)","status":"phase_3"}]}],"pipeline":[{"name":"AVTX-803","genericName":"AVTX-803","slug":"avtx-803","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVTX-803 (L-Fucose)","genericName":"AVTX-803 (L-Fucose)","slug":"avtx-803-l-fucose","phase":"phase_3","mechanism":"L-Fucose is a simple sugar that enhances the fucosylation of antibodies and immune cells to improve their effector functions and anti-tumor activity.","indications":["Advanced solid tumors (in combination with monoclonal antibodies)","Hematologic malignancies"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdW85SGdHcTBMSmtQYWJyRVF5NEJ3NHlXUTRzbm81YjZFcGN1eHJhelhMX3pkT2FCR25vWXZQQnZUSmczUHg3X2k5VVdtbUhQTGVScGNsTEkwbW5ITi1RMmVYQ2UwZUJMOGpwbXE5OTMwMkpYcHhROHhMb0F1TVh5WTRrbHE5dUdmSEpULXh4ZlFMbVp2bmFzRGhKSGI1b3BtRElUWE1HQlRkdw?oc=5","date":"2025-10-23","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces – Pharma and biotech hires – August and September 2025 - pharmaphorum","headline":"Changing Faces – Pharma and biotech hires – August and September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNWlJ6Q3BXcXZJYUlzMkdhOHhLMUdOY1R0U3hDUE9BZWlRZDYzZEJNZE1Tbm51U0xySnJ6Y3V6c3YwWjVqMXpib0JuNDNpajF6WUZ5RW1KOVhTZkg0eDJXQUR6cEh1aFExcjBOVGQzbk9Hb1JEbkh4NkI2LVQzYjdFS2N2WHZDa2d5X21BSjFkNElMeUxiYTFMSHNLSmYyM3FWT2c?oc=5","date":"2025-08-28","type":"regulatory","source":"PharmaTimes","summary":"Coya Therapeutics to progress trial of ALS treatment upon FDA approval - PharmaTimes","headline":"Coya Therapeutics to progress trial of ALS treatment upon FDA approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZ29uV1VFellMb3dBVmpDUGp1aUd2YUtqNmUzcnY3eFRYQzViXzZ0R2gxUHR2VGZwREFwSVdFQ1pjSElhVk1oUHdOcUtYOGlKRXo5OE8yUXhBcFBDVHlUd3Rfa0h2dDdHOVZkVnVfVVlEMkQ3ODdGN0F1QUNYbHZrUkpQRTZfVW02QzFFaVN1T1lwR3dFSlpvcDU2a1Rlb2dCalVQajZFcXQ2NXRpTnNUd0NFbVdudw?oc=5","date":"2025-08-21","type":"pipeline","source":"Fierce Pharma","summary":"Sarepta extends $700M debt to 2030, adds private placement amid Elevidys uncertainty - Fierce Pharma","headline":"Sarepta extends $700M debt to 2030, adds private placement amid Elevidys uncertainty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNbS12eHAxMlh6VWZVdnpOZ2ZmbDZRd3JOUktsWkEzV1dlUWQyLUpnU0taRHU1QkVVT180eGNuV0diaHpqaFB4MHAyT2JlLXpzYVB4MXBzVlptZ193MG1oMUtYa3dxWTlVUThoTDcyNmxQMDE3WUdidmRfLVR4NlhBVUdfNGZ4ZThyc2tPOXBUWWlhVHJmVG5xb0xNTFpGUmxINmxFS0kxckYwSUxkeXhva1B1N0szdEtYWVVIWXRDazlDcGluckJQMTRHbk9ZMFV4VUVNdE1zVHl1cUFxcndPLVBOOU51bTJBYk1vbFItM2FmUVRkQkE?oc=5","date":"2025-08-20","type":"pipeline","source":"PR Newswire","summary":"Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 - PR Newswire","headline":"Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQTjM5RlNXbFpPdUQxV09DMnRkakNlTWh2RlZvODdzMmtYZVJRbTE2OXRsQU1NYnBQUUE2cUM5a2FScjg3YzVSTWo0VE1UbEt0a1BGcFV1am1Rcy1VZ3ozeEJOVHZSVTgyb294VW45Znh4aWZQUUtFcjFOSjNwYzRXeDkzNEs2TU5UYVhqNHN3ZGJMeGZpbWpIYXVQTXJlbVl6ZTFCRjZlb0pUcS1wODEzdlpSelAwaGlZRi1BSXhfY2JILXhCSjhmazJrdEtCMENOdGlnYkdYMkl3WWFhay1Ed2hMWkR0VU9zVGx2OS0zdUhDM2Q5STdjdldhcGE4VGQ0U2J6Mk5NdFFCZw?oc=5","date":"2025-08-20","type":"regulatory","source":"GlobeNewswire","summary":"Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewswire","headline":"Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-15","type":"pipeline","source":"simplywall.st","summary":"High Growth Tech Stocks To Watch In The US August 2025 - simplywall.st","headline":"High Growth Tech Stocks To Watch In The US August 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQQW1mb0pyQmRoZHZpQVRSOHdybWs5eXRDbE5sNEphNjY1RC0xYnhfUG56X2djc2VWNWdYajNnd3BZMXZTVlhFY2NFWl9sUW1oWllWZjJtMzdOUEo4a0Y4SW5ycUdKV1FCMnhCd0pFRkhvaFVyTktIYk02MXFDd1BOcHI4M1EzYU0zWGFKUWl2VnRaX080TTFORkpxVGpIREt3T1VqNVQ5SEtkZ3U1RUZJZ0lCVFdnNVFMZWdWUE5ENA?oc=5","date":"2025-08-14","type":"regulatory","source":"veronapress.com","summary":"Council approves plans for pharmaceutical manufacturing facility - veronapress.com","headline":"Council approves plans for pharmaceutical manufacturing facility","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxObmxUbVJMMjBqVTI0Y3BvZTJmdWdiTEdHSnpIbUpIZWp0WFp6MXUxaFFXSnhYVVhZYno5Y2VGZDJ3UjFZcWR3V1J1aURGXy1YODdyanRIczhUUTdKYWZzOHNOTFZZNjVkb2w0cEJGN1BpdkhYdkpFdHdxa2RycUxlTXVUaTJ5RmdHN1hWZHdWOG5QZGNKa2o3bUhCWU5lWWtLY01SZlU4dFNRMVptaEdNQ21Xckx0cHlTRkxwcUFENXk0dw?oc=5","date":"2025-08-13","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics - Arrowhead Pha","headline":"Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Millio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMXFtTDhyNnpsYnBZR0FfQmtpUmwtVl9ldGt1RGNObXFxMi0zX0ZMS2R5aFB2Vy1SUFhPU1E0U0lKR18wRGpnM2R5cFpwTEZpMXVtZnhuVEM5OENtQ1FKUkt1SXZUR1oxeV9OcXRjMmRjVVY3azdSeVJEZjFrWHRreEFMRmxZYzVUSzBCWUd2eWF2cUc1U0plMQ?oc=5","date":"2025-08-04","type":"pipeline","source":"Yahoo Finance","summary":"Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - Yahoo Finance","headline":"Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxONllKM1Y4ZUFQU3p1ZzB2OHRZUFA4MHBUd1pGUV9qVEIzMTM1VEo4OS1KNk5rNmtneW1oRm1rWDNuS1RBZFBxMk1pcTltX1l0M0ZTVG5Vd01sVm1TQzg3Nkk4V241S1VGU1F0eHFxczk1a08tcy1mbnhac1hvZE5nS3JtRkExaFlsdFFPeHRoMDh1U0JRdG1LZTZfRUpxejNJRDVLYm5fY3pnVUUwblN0TXVzUWI2dzZuQlJyanN1RjNOekVzVnpR?oc=5","date":"2025-08-01","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Arro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcWtkTFh5NXh0ekg3ekd2UTREVWplNlBnbGJpVHZ0YWlYRXdzdEJOQ0VxSDJYY1QtRnA0SzQzU2V4RWlkTWctSmMxQ3lmSl9MdUI5S05vaklaMUM2N2pIQm9OUG8zdWotWnktMmtGQldEVEs2REowT2NVa3ktU19zMjB1Rmd2ejR0WFhfdXhBbzNFTktxRXZjRTRJQmQ3dDlnUm1NUTVmQkNiVzZQTDhxZUF3WWFjdFREb3JUMG95VWx0UQ?oc=5","date":"2025-07-24","type":"earnings","source":"BioSpace","summary":"Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025 - BioSpace","headline":"Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}